nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
Company profile
Ticker
NBRVF
Exchange
Website
CEO
Theodore Schroeder
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nabriva Therapeutics AG
SEC CIK
Corporate docs
Subsidiaries
Nabriva Therapeutics GmbH • Nabriva Therapeutics Ireland • Zavante Therapeutics, Inc. • Nabriva Therapeutics US, Inc. ...
NBRVF stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
25 Oct 23
EFFECT
Notice of effectiveness
25 Oct 23
POS AM
Prospectus update (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
Transcripts
NBRVF
Earnings call transcript
2022 Q3
14 Nov 22
NBRVF
Earnings call transcript
2022 Q2
4 Aug 22
NBRVF
Earnings call transcript
2022 Q1
8 May 22
NBRVF
Earnings call transcript
2021 Q4
30 Mar 22
NBRVF
Earnings call transcript
2021 Q3
10 Nov 21
NBRVF
Earnings call transcript
2021 Q2
6 Aug 21
NBRVF
Earnings call transcript
2021 Q1
9 May 21
NBRVF
Earnings call transcript
2020 Q4
12 Mar 21
NBRVF
Earnings call transcript
2020 Q3
9 Nov 20
NBRVF
Earnings call transcript
2020 Q2
9 Aug 20
Latest ownership filings
3
H MICHAEL HOGAN III
10 Jul 23
3
David Maggio
10 Jul 23
4
Steven P. Gelone
31 Jan 23
4
Theodore R Schroeder
31 Jan 23
4
Steven P. Gelone
10 Jan 23
4
Theodore R Schroeder
10 Jan 23
4
Theodore R Schroeder
4 Jan 23
4
Steven P. Gelone
4 Jan 23
4
Steven P. Gelone
8 Dec 22
4
Theodore R Schroeder
8 Dec 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.26 mm | 2.26 mm | 2.26 mm | 2.26 mm | 2.26 mm | 2.26 mm |
Cash burn (monthly) | (no burn) | 1.49 mm | 4.02 mm | 4.54 mm | (no burn) | 1.08 mm |
Cash used (since last report) | n/a | 14.70 mm | 39.62 mm | 44.69 mm | n/a | 10.60 mm |
Cash remaining | n/a | -12.45 mm | -37.36 mm | -42.44 mm | n/a | -8.34 mm |
Runway (months of cash) | n/a | -8.3 | -9.3 | -9.4 | n/a | -7.8 |
Institutional ownership, Q2 2023
41.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 92.23 mm |
Total shares | 13.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vivo Capital VIII | 4.80 mm | $12.05 mm |
Lincoln Park Capital Fund | 4.51 mm | $4.65 mm |
Frazier Healthcare VII | 4.01 mm | $13.24 mm |
Values First Advisors | 27.26 k | $41.17 mm |
Renaissance Technologies | 22.86 k | $35.00 k |
MS Morgan Stanley | 5.35 k | $8.08 mm |
Advisor | 2.01 k | $3.12 mm |
BAC Bank Of America | 84.00 | $127.00 k |
RY Royal Bank Of Canada | 22.00 | $0.00 |
Activest Wealth Management | 13.00 | $9.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 23 | Theodore R Schroeder | Ordinary Shares | Payment of exercise | Dispose F | No | No | 1.5 | 431 | 646.50 | 11,989 |
29 Jan 23 | Steven P. Gelone | Ordinary Shares | Payment of exercise | Dispose F | No | No | 1.5 | 140 | 210.00 | 14,283 |
6 Jan 23 | Theodore R Schroeder | Ordinary Shares | Payment of exercise | Dispose F | No | No | 1.3 | 11 | 14.30 | 12,420 |
6 Jan 23 | Steven P. Gelone | Ordinary Shares | Payment of exercise | Dispose F | No | No | 1.3 | 5 | 6.50 | 14,423 |
31 Dec 22 | Steven P. Gelone | Ordinary Shares | Payment of exercise | Dispose F | No | No | 1.89 | 3 | 5.67 | 14,428 |